George Jeffrey P. 4

What Happened

• Jeffrey P. George, a director of Amneal Pharmaceuticals (AMRX), had restricted stock units (RSUs) convert and recorded a new RSU grant. The filing shows a conversion/exercise of 34,819 derivative units on May 7, 2026 (reported as acquired and simultaneously disposed at $0) and a separate RSU award of 19,824 units on May 6, 2026 (acquired, $0).
• The reported transactions show no cash paid or received (prices listed as $0.00 for the disposal and grant). Total cash proceeds are $0 per the filing.

Key Details

• Transaction dates/prices:
  • 2026-05-07: Conversion/exercise of 34,819 derivative units — acquired (N/A) and disposed at $0.00.
  • 2026-05-06: Grant/award of 19,824 restricted stock units at $0.00.
• Shares owned after transaction: Not stated in the provided filing details.
• Footnotes:
  • F1: Each RSU represents a contingent right to receive one share of Class A common stock.
  • F2: The 34,819 RSUs were originally granted on May 6, 2025 and vested on May 7, 2026.
  • F3: Vesting occurs on the later of (i) the day before the issuer's first annual meeting after grant and (ii) the day after the first anniversary of the grant.
• Filing/timeliness: Report filed May 8, 2026 for transactions with period ending May 6, 2026; appears to have been filed promptly.

Context

• These are derivative/award-related events (RSU vesting and grant), not open-market purchases or sales. The conversion of RSUs into shares and a simultaneous $0.00 disposition commonly reflects a net settlement or share withholding (e.g., to satisfy tax withholding), but the filing does not explicitly state the reason.
• Awards and vesting are routine insider compensation/activity and do not by themselves indicate buy/sell sentiment in the market.